Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Atadja

Showing results (101-110 of 102) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 102 results.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Pageof 11

Showing results (101-110 of 102) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 102 results.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Nature Medicine|October 20, 2015
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Joshua M Korn, Stéphane Ferretti, et al.
Pageof 11